{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T04:12:19Z","timestamp":1754194339643},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Studies on therapeutic drug monitoring (TDM) of second-generation antipsychotics (SGAs) have provided conflicting results regarding the association between dose, plasma concentrations, and drug effect and have focused rather on analyzing how individual drugs work. No study has attempted to process data from different SGAs globally to offer a panoramic view of the utility of TDM in clinical practice, and data on patients with first-episode psychosis (FEP) are lacking. This study aimed to assess the relationship between dose, plasma concentrations, and drug effect in a sample of patients with FEP, regardless of the SGA prescribed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Data from 64 compliant patients treated with the same SGA during a 2-month follow-up were recorded. Clinical symptoms were assessed using the Positive and Negative Symptoms Scale and the Montgomery\u2013\u00c5sberg Depression Rating Scale. Adverse effects were rated using the Udvalg f\u00fcr Kliniske Undersogelser scale. SGA doses were standardized to chlorpromazine equivalents, and patients were classified into 3 different ranges according to their plasma concentrations (subtherapeutic, therapeutic, and supratherapeutic).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Plasma concentration ranges were proportionally related to dose. Patients with supratherapeutic plasma concentrations were treated with doses significantly higher than those with subtherapeutic concentrations. Dose and plasma concentrations were not associated with early drug effect.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>TDM seems unable to accurately estimate the early effects of SGAs in FEP. Ours is the first study to categorize plasma concentrations of SGAs into ranges for joint processing of data from a larger number of patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000480","type":"journal-article","created":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T17:21:33Z","timestamp":1516814493000},"page":"257-267","source":"Crossref","is-referenced-by-count":8,"title":["Therapeutic Drug Monitoring of Second-Generation Antipsychotics for the Estimation of Early Drug Effect in First-Episode Psychosis: A Cross-sectional Assessment"],"prefix":"10.1097","volume":"40","author":[{"given":"Mariana","family":"Bustillo","sequence":"first","affiliation":[{"name":"Early Psychosis Unit, BioCruces Health Research Institute, Barakaldo;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arantzazu","family":"Zabala","sequence":"additional","affiliation":[{"name":"Early Psychosis Unit, BioCruces Health Research Institute, Barakaldo;"},{"name":"Department of Neurosciences, University of the Basque Country, UPV\/EHU, Leioa, Bizkaia, Spain;"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental, CIBERSAM, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imanol","family":"Querejeta","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of the Basque Country, UPV\/EHU, Leioa, Bizkaia, Spain;"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental, CIBERSAM, Spain;"},{"name":"Department of Psychiatry, Donostia University Hospital;"},{"name":"Biodonostia Health Research Institute, Donostia, Gipuzkoa, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaione I.","family":"Carton","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of the Basque Country, UPV\/EHU, Leioa, Bizkaia, Spain;"},{"name":"Department of Psychiatry, Donostia University Hospital;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oiane","family":"Mentxaka","sequence":"additional","affiliation":[{"name":"Early Psychosis Unit, BioCruces Health Research Institute, Barakaldo;"},{"name":"Department of Neurosciences, University of the Basque Country, UPV\/EHU, Leioa, Bizkaia, Spain;"},{"name":"Department of Psychiatry, Cruces University Hospital, Barakaldo, Bizkaia. Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Gonz\u00e1lez-Pinto","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of the Basque Country, UPV\/EHU, Leioa, Bizkaia, Spain;"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental, CIBERSAM, Spain;"},{"name":"Department of Psychiatry, Araba University Hospital;"},{"name":"Bioaraba Health Research Institute, Vitoria-Gasteiz, Araba. Spain; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sainza","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of the Basque Country, UPV\/EHU, Leioa, Bizkaia, Spain;"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental, CIBERSAM, Spain;"},{"name":"Department of Psychiatry, Araba University Hospital;"},{"name":"Bioaraba Health Research Institute, Vitoria-Gasteiz, Araba. Spain; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Javier","family":"Meana","sequence":"additional","affiliation":[{"name":"Early Psychosis Unit, BioCruces Health Research Institute, Barakaldo;"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental, CIBERSAM, Spain;"},{"name":"Department of Pharmacology, University of the Basque Country, UPV\/EHU, Leioa, Bizkaia. Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Ignacio","family":"Eguiluz","sequence":"additional","affiliation":[{"name":"Early Psychosis Unit, BioCruces Health Research Institute, Barakaldo;"},{"name":"Department of Neurosciences, University of the Basque Country, UPV\/EHU, Leioa, Bizkaia, Spain;"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental, CIBERSAM, Spain;"},{"name":"Department of Psychiatry, Cruces University Hospital, Barakaldo, Bizkaia. Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Segarra","sequence":"additional","affiliation":[{"name":"Early Psychosis Unit, BioCruces Health Research Institute, Barakaldo;"},{"name":"Department of Neurosciences, University of the Basque Country, UPV\/EHU, Leioa, Bizkaia, Spain;"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental, CIBERSAM, Spain;"},{"name":"Department of Psychiatry, Cruces University Hospital, Barakaldo, Bizkaia. Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230928","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1192\/bjp.178.6.506","article-title":"Recovery from psychotic illness: a 15-and 25-year international follow-up study","volume":"178","author":"Harrison","year":"2001","journal-title":"Br J Psychiatry."},{"key":"R3-20230928","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/schbul\/sbi017","article-title":"Predicting recovery from schizophrenia: a retrospective comparison of characteristics at onset of people with single and multiple episodes","volume":"31","author":"Rosen","year":"2005","journal-title":"Schizophr Bull."},{"key":"R5-20230928","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","article-title":"Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder","volume":"56","author":"Robinson","year":"1999","journal-title":"Arch Gen Psychiatry."},{"key":"R6-20230928","doi-asserted-by":"crossref","first-page":"20S","DOI":"10.1097\/00004714-199804001-00005","article-title":"The development of treatment resistance in patients with schizophrenia: a clinical and pathophysiologic perspective","volume":"18","author":"Lieberman","year":"1998","journal-title":"J Clin Psychopharmacol."},{"key":"R7-20230928","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1176\/ajp.156.4.544","article-title":"Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder","volume":"156","author":"Robinson","year":"1999","journal-title":"Am J Psychiatry."},{"key":"R8-20230928","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/schbul\/23.4.653","article-title":"The evaluation and treatment of first-episode psychosis","volume":"23","author":"Sheitman","year":"1997","journal-title":"Schizophr Bull."},{"key":"R9-20230928","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.2165\/00003495-200363210-00001","article-title":"Pharmacological management of first-episode schizophrenia and related nonaffective psychoses","volume":"63","author":"Bradford","year":"2003","journal-title":"Drugs."},{"key":"R10-20230928","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1176\/appi.ajp.158.11.1835","article-title":"Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia","volume":"158","author":"Gitlin","year":"2001","journal-title":"Am J Psychiatry."},{"key":"R11-20230928","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/JCP.0000000000000523","article-title":"Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review","volume":"36","author":"Garcia","year":"2016","journal-title":"J Clin Psychopharmacol."},{"key":"R12-20230928","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.schres.2012.05.007","article-title":"Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies","volume":"139","author":"Alvarez-Jimenez","year":"2012","journal-title":"Schizophr Res."},{"key":"R13-20230928","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jpsychires.2012.05.001","article-title":"Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study","volume":"46","author":"Caseiro","year":"2012","journal-title":"J Psychiatr Res."},{"key":"R14-20230928","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1034\/j.1600-0447.2002.02437.x","article-title":"Medication adherence of individuals with a first episode of psychosis","volume":"106","author":"Coldham","year":"2002","journal-title":"Acta Psychiatr Scand."},{"key":"R15-20230928","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/01.pra.0000336756.65308.83","article-title":"A review of second-generation antipsychotic discontinuation in first-episode psychosis","volume":"14","author":"Miller","year":"2008","journal-title":"J Psychiatr Pract."},{"key":"R16-20230928","doi-asserted-by":"crossref","first-page":"45","DOI":"10.9758\/cpn.2011.9.2.45","article-title":"Second-generation antipsychotic discontinuation in first episode psychosis: an updated review","volume":"9","author":"Miller","year":"2011","journal-title":"Clin Psychopharmacol Neurosci."},{"key":"R17-20230928","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/tpj.2016.44","article-title":"Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes","volume":"16","author":"Mas","year":"2016","journal-title":"Pharmacogenomics J."},{"key":"R18-20230928","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr Bull."},{"key":"R19-20230928","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2165\/11314280-000000000-00000","article-title":"Antipsychotic drugs for first-episode schizophrenia: a comparative review","volume":"23","author":"Salimi","year":"2009","journal-title":"CNS Drugs."},{"key":"R20-20230928","article-title":"The relapse rate and predictors of relapse in patients with first-episode psychosis following discontinuation of antipsychotic medication","volume":"9999","author":"Di Capite","year":"2016","journal-title":"Early Interv Psychiatry."},{"key":"R21-20230928","doi-asserted-by":"crossref","first-page":"492","DOI":"10.4088\/JCP.14m09540","article-title":"Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study","volume":"77","author":"Mayoral-van Son","year":"2016","journal-title":"J Clin Psychiatry."},{"key":"R22-20230928","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1001\/archgenpsychiatry.2011.150","article-title":"Progressive brain changes in children and adolescents with first-episode psychosis","volume":"69","author":"Arango","year":"2012","journal-title":"Arch Gen Psychiatry."},{"key":"R23-20230928","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/oxfordjournals.schbul.a033315","article-title":"Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort","volume":"24","author":"Wiersma","year":"1998","journal-title":"Schizophr Bull."},{"key":"R25-20230928","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/NDT.S96392","article-title":"Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review","volume":"12","author":"Karson","year":"2016","journal-title":"Neuropsychiatr Dis Treat."},{"key":"R26-20230928","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00007691-200404000-00012","article-title":"Therapeutic monitoring of new antipsychotic drugs","volume":"26","author":"Hiemke","year":"2004","journal-title":"Ther Drug Monit."},{"key":"R27-20230928","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry."},{"key":"R28-20230928","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.schres.2013.04.002","article-title":"Plasma levels of second-generation antipsychotics and clinical response in acute psychosis: a review of the literature","volume":"147","author":"Lopez","year":"2013","journal-title":"Schizophr Res."},{"key":"R29-20230928","first-page":"171","article-title":"Validacion de la escala de los sindromes positivo y negativo (IPANSS) en una muestra de esquizofrenicos espanoles","volume":"22","author":"Peralta Mart\u00edn","year":"1994","journal-title":"Actas Luso Esp Neurol Psiquiatr Cienc Afines."},{"key":"R30-20230928","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0025-7753(02)72429-9","article-title":"Validation of the Spanish versions of the montgomery-asberg depression and hamilton anxiety rating scales [in Spanish]","volume":"118","author":"Chamorro","year":"2002","journal-title":"Med Clin (Barc)."},{"key":"R31-20230928","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.eurpsy.2009.02.005","article-title":"Early improvement as a predictor of remission and response in schizophrenia: results from a naturalistic study","volume":"24","author":"Jager","year":"2009","journal-title":"Eur Psychiatry."},{"key":"R32-20230928","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/npp.2009.164","article-title":"Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia","volume":"35","author":"Kinon","year":"2010","journal-title":"Neuropsychopharmacology."},{"key":"R33-20230928","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1192\/bjp.bp.109.069328","article-title":"An early improvement threshold to predict response and remission in first-episode schizophrenia","volume":"196","author":"Schennach-Wolff","year":"2010","journal-title":"Br J Psychiatry."},{"key":"R34-20230928","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/00004714-200210000-00019","article-title":"Effects of olanzapine plasma concentrations on depressive symptoms in schizophrenia: a pilot study","volume":"22","author":"Lane","year":"2002","journal-title":"J Clin Psychopharmacol."},{"key":"R35-20230928","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/archpsyc.55.3.250","article-title":"Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol","volume":"55","author":"Tollefson","year":"1998","journal-title":"Arch Gen Psychiatry."},{"key":"R36-20230928","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr Scand Suppl."},{"key":"R37-20230928","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/00007691-200312000-00006","article-title":"Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia","volume":"25","author":"Fellows","year":"2003","journal-title":"Ther Drug Monit."},{"key":"R38-20230928","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1600-0447.2006.00840.x","article-title":"Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication","volume":"114","author":"Nesvag","year":"2006","journal-title":"Acta Psychiatr Scand."},{"key":"R39-20230928","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/FTD.0b013e3181956726","article-title":"Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole","volume":"31","author":"Waade","year":"2009","journal-title":"Ther Drug Monit."},{"key":"R40-20230928","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"Am J Psychiatry."},{"key":"R41-20230928","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00007691-200302000-00007","article-title":"Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication","volume":"25","author":"Gex-Fabry","year":"2003","journal-title":"Ther Drug Monit."},{"key":"R42-20230928","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00007691-199902000-00017","article-title":"Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors","volume":"21","author":"Balant Gorgia","year":"1999","journal-title":"Ther Drug Monit."},{"key":"R43-20230928","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/0269881105053306","article-title":"Influence of age and gender on risperidone plasma concentrations","volume":"19","author":"Aichhorn","year":"2005","journal-title":"J Psychopharmacol."},{"key":"R44-20230928","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/JCP.0b013e3181ee2afe","article-title":"Effect of adjunctive duloxetine on the plasma concentrations of clozapine, olanzapine, and risperidone in patients with psychotic disorders","volume":"30","author":"Santoro","year":"2010","journal-title":"J Clin Psychopharmacol."},{"key":"R45-20230928","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/0091270004269870","article-title":"Pharmacokinetics of aripiprazole and concomitant lithium and valproate","volume":"45","author":"Citrome","year":"2005","journal-title":"J Clin Pharmacol."},{"key":"R46-20230928","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.4088\/JCP.v68n1011","article-title":"Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service","volume":"68","author":"Castberg","year":"2007","journal-title":"J Clin Psychiatry."},{"key":"R47-20230928","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2125.2011.03941.x","article-title":"Possible drug-drug interaction between quetiapine and lamotrigine\u2014evidence from a Swedish TDM database","volume":"72","author":"Andersson","year":"2011","journal-title":"Br J Clin Pharmacol."},{"key":"R48-20230928","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.forsciint.2012.01.002","article-title":"Screening and quantification of antipsychotic drugs in human brain tissue by liquid chromatography-tandem mass spectrometry: application to postmortem diagnostics of forensic interest","volume":"219","author":"Sampedro","year":"2012","journal-title":"Forensic Sci Int."},{"key":"R49-20230928","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1600-0447.2007.00992.x","article-title":"Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?","volume":"115","author":"Buckley","year":"2007","journal-title":"Acta Psychiatr Scand."},{"key":"R50-20230928","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0013-7006(04)95474-7","article-title":"Efficacy of atypical antipsychotics in depressive syndromes [in French]","volume":"30","author":"Quintin","year":"2004","journal-title":"Encephale."},{"key":"R51-20230928","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1038\/sj.npp.1301325","article-title":"Defining \u201cresponse\u201d in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs","volume":"32","author":"Leucht","year":"2007","journal-title":"Neuropsychopharmacology."},{"key":"R52-20230928","first-page":"52","article-title":"What is the relevance of a 2-week response to an antipsychotic?","volume":"13","author":"Webster","year":"2014","journal-title":"Curr Psychiatr."},{"key":"R53-20230928","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1176\/ajp.2006.163.4.743","article-title":"Time course for antipsychotic treatment response in first-episode schizophrenia","volume":"163","author":"Emsley","year":"2006","journal-title":"Am J Psychiatry."},{"key":"R54-20230928","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.biopsych.2005.02.023","article-title":"Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended","volume":"57","author":"Leucht","year":"2005","journal-title":"Biol Psychiatry."},{"key":"R55-20230928","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1055\/s-2004-815527","article-title":"Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients","volume":"37","author":"Bergemann","year":"2004","journal-title":"Pharmacopsychiatry."},{"key":"R56-20230928","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/JCP.0b013e31828b28d5","article-title":"Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response","volume":"33","author":"Bishara","year":"2013","journal-title":"J Clin Psychopharmacol."},{"key":"R57-20230928","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/JCP.0b013e3181a289cb","article-title":"Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg\/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration","volume":"29","author":"Citrome","year":"2009","journal-title":"J Clin Psychopharmacol."},{"key":"R58-20230928","first-page":"13","article-title":"The pharmacokinetics of risperidone in humans: a summary","volume":"55","author":"Heykants","year":"1994","journal-title":"J Clin Psychiatry."},{"key":"R59-20230928","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.eurpsy.2004.09.009","article-title":"Clinical outcome and olanzapine plasma levels in acute schizophrenia","volume":"20","author":"Mauri","year":"2005","journal-title":"Eur Psychiatry."},{"key":"R60-20230928","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0378-4347(97)00302-2","article-title":"Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs","volume":"698","author":"Olesen","year":"1997","journal-title":"J Chromatogr B Biomed Sci Appl."},{"key":"R61-20230928","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/JCP.0b013e318221b408","article-title":"Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999\u20132009","volume":"31","author":"Patel","year":"2011","journal-title":"J Clin Psychopharmacol."},{"key":"R62-20230928","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/01.jcp.0000186242.26050.1e","article-title":"Plasma risperidone levels and clinical response in patients with first-episode psychosis","volume":"25","author":"Verma","year":"2005","journal-title":"J Clin Psychopharmacol."},{"key":"R63-20230928","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000054932","article-title":"Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study","volume":"44","author":"Yoshimura","year":"2001","journal-title":"Neuropsychobiology."},{"key":"R64-20230928","first-page":"88","article-title":"Risperidone clinical efficacy: role of the metabolite 9-hydroxy-risperidone","volume":"30","author":"Anderson","year":"1994","journal-title":"Psychopharmacol Bull."},{"key":"R65-20230928","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/JCP.0b013e31817e63a5","article-title":"Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study","volume":"28","author":"Kinon","year":"2008","journal-title":"J Clin Psychopharmacol."},{"key":"R66-20230928","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4088\/JCP.v61n0311","article-title":"Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels","volume":"61","author":"Lane","year":"2000","journal-title":"J Clin Psychiatry."},{"key":"R67-20230928","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s002130000576","article-title":"Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia","volume":"153","author":"Spina","year":"2001","journal-title":"Psychopharmacology (Berl)."},{"key":"R68-20230928","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/01.jcp.0000115663.45074.8a","article-title":"A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder","volume":"24","author":"Huq","year":"2004","journal-title":"J Clin Psychopharmacol."},{"key":"R69-20230928","doi-asserted-by":"crossref","first-page":"885","DOI":"10.4088\/JCP.v63n1006","article-title":"Risperidone, 2 mg\/day vs. 4 mg\/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning","volume":"63","author":"Merlo","year":"2002","journal-title":"J Clin Psychiatry."},{"key":"R70-20230928","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1440-1819.2003.01212.x","article-title":"Correlation between scores on Continuous Performance Test and plasma concentration for schizophrenic patients on risperidone","volume":"58","author":"Chen","year":"2004","journal-title":"Psychiatry Clin Neurosci."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201804000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T01:07:16Z","timestamp":1695863236000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201804000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000480","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}